Journal of Clinical Oncology · 1986 · 439 citations · 26 references
MedicineOncologyPathologyChemotherapyHematologic OncologyMedical OncologyChemotherapy In Hematologic MalignanciesHematologic MalignanciesHematologic Malignancy TherapyImmunosuppressionLymphoid TumorsRelapsed DiseaseComplete Response AssessmentHodgkin Lymphoma TherapyHodgkin Lymphoma TreatmentLymphoma ChemotherapyLymphoma RelapseLymphoma Treatment ResponseNon-hodgkin Lymphoma TherapyNon-hodgkin Lymphoma Treatment
The results of treatment of 198 patients with MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) for Hodgkin's disease were analyzed after a median of 14 years of follow-up. Throughout the period of follow-up, 103 patients have remained continuously free of disease. Review of biopsy specimens of 43 patients originally classified as Hodgkin's disease, lymphocyte-depleted type, revealed that ten of these patients actually had diffuse immunoblastic or large cell non-Hodgkin's lymphomas. Of the 188 patients with Hodgkin's disease, 157 achieved a complete response (CR) (84%), and 66% of them (101 patients) have remained disease-free more than 10 years from the end of treatment. Absence of B symptoms and receiving higher doses of vincristine were factors associated with a higher CR rate and longer survival. Patients entering complete remission in five cycles or less had significantly longer remissions than those requiring six or more cycles. Forty-eight percent of the Hodgkin's disease patients have survived between 9 and 21 years (median, 14 years) from the end of treatment. Nineteen percent of the CRs have died of intercurrent illnesses, free of Hodgkin's disease.
26
The pathology and nomenclature of Hodgkin's disease.
Talvalkar Gv · PubMed · 1972 · 762 citations
Curability of Advanced Hodgkin's Disease with Chemotherapy
Vincent T. DeVita · Annals of Internal Medicine · 1980 · 474 citations
Medicine, Oncology, Pharmacotherapy +15